IP Library Granted Patent US 7,455,839
Granted Patent B2
US 7,455,839 · App. 10/696,717 · Granted Nov 25, 2008

Method of inhibiting the formation of inhibin/betaglycan complexes with an anti-betaglycan antibody

Assignee: Research Development Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,455,839
App. No.
10/696,717
Granted
Nov 25, 2008
Kind
B2
Abstract

Inhibins and activins are protein hormones that reciprocally modulate a diversity of regulatory pathways. Competitive binding experiments revealed that betaglycan, the type III TGF-β receptor, also functions as an inhibin receptor. Betaglycan augments the binding of inhibin to the ActRII activin receptor. By augmenting inhibin binding to ActRII, betaglycan effectively sequesters ActRII away from activin and thereby reduces activin signaling. In addition, the ActRII-betaglycan complex may generate novel signals distinct from those initiated by activin signaling via ActRII and ALK4. Betaglycan is produced in discrete nuclei of the rat brain and by specific cell types within the adult rat pituitary, testis, and ovary. The presence of betaglycan within inhibin-responsive tissues and cell types, together with the ability of this protoglycan to bind inhibin and to confer inhibin sensitivity, is consistent with a role of betaglycan as an inhibin-specific receptor mediating inhibin responses within various tissues.

Claims (4)

1. A method of inhibiting the formation of inhibin/betaglycan complexes on the surface of a cell by contacting the cell with an anti-betaglycan antibody.

2. The method of claim 1 , wherein activin-induced signaling in the cell is increased.

3. The method of claim 1 , wherein the method is used to treat a reproductive disorder.

4. The method of claim 3 , wherein the reproductive disorder is reduced fertility.

Assignments (1)
CONFIRMATORY LICENSE Recorded Mar 17, 2015
From: SALK INSTITUTE FOR BIOLOGICAL STUDIES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035220/0888 →
Continuity (3)
Division 0973817100 · Dec 15, 2000
Provisional Application 6017097100 · Dec 15, 1999
Related Publication 20040258689A1 · Dec 23, 2004